Nascimento Sara, Rodrigues Marta, Gonçalves Henriques Manuel, Paixão Duarte Fernanda, Barra António, Matos Teresa
Hospital Prof. Doutor Fernando Fonseca, IC 19, 2760-276, Amadora, Portugal.
Case Rep Womens Health. 2020 Jun 30;27:e00238. doi: 10.1016/j.crwh.2020.e00238. eCollection 2020 Jul.
The anti-PP1Pk is a rare antibody associated with recurrent miscarriages, mainly in the first half of pregnancy. There seems to be a direct correlation between the antibody titer and risk of miscarriage. As this is a rare entity, few case reports have been published. The most frequently proposed therapeutic approaches are double-filtration plasmapheresis and plasma exchange therapy. The rationale behind them is to remove the cytotoxic antibodies from maternal circulation. Here, we present the case of a 30-year-old woman with a history of two spontaneous miscarriages and a pre-conception anti-PP1Pk antibody titer of 1:4. As soon as she became pregnant, she was placed on prednisolone and low-molecular-weight heparin (LMWH). Biweekly antibody titers were performed throughout the entire gestation and remained below 1:16. As the titers were considered to be low, plasmapheresis was not performed. The pregnancy was uneventful and she delivered a healthy newborn child at 37 weeks of gestation, with no signs of anaemia.
抗PP1Pk抗体是一种与复发性流产相关的罕见抗体,主要发生在妊娠前半期。抗体滴度与流产风险之间似乎存在直接关联。由于这是一种罕见病症,已发表的病例报告很少。最常采用的治疗方法是双重过滤血浆置换和血浆置换疗法。其背后的原理是从母体循环中清除细胞毒性抗体。在此,我们报告一例30岁女性病例,该女性有两次自然流产史,孕前抗PP1Pk抗体滴度为1:4。她一旦怀孕,就开始服用泼尼松龙和低分子肝素(LMWH)。在整个妊娠期每两周检测一次抗体滴度,结果均低于1:16。由于滴度被认为较低,未进行血浆置换。此次妊娠过程顺利,她在妊娠37周时产下一名健康新生儿,无贫血迹象。